KRAS and neoplasm: Recent reports have highlighted superior anti-tumor activity of the combinations of dual PI3K-AKT-mTOR inhibitors with MEK-ERK1/2 inhibitors against tumors that express mutant K-RAS and exhibit increased activity of PI3K-AKT-mTOR pathway (Figure 6) [31, 45].